Copenhagen, Denmark
Copenhagen, Denmark

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsvaerd, Denmark, with production facilities in seven countries, and affiliates or offices in 75 countries.Novo Nordisk manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with haemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza.Novo Nordisk employs more than 40,000 people globally, and marketed its products in 180 countries. It is the largest publicly traded company in the Nordic countries by market capitalization. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt.Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations .The company was ranked 25th among 100 best companies to work for in 2010 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth. Novo Nordisk was ranked 72nd on “Fortune’s 100 Best Companies to Work For®” list within the U.S. state of New Jersey as of January 2014. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Novo Nordisk AS | Date: 2017-01-19

Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.


Patent
Novo Nordisk AS | Date: 2017-03-08

A protein purification process with virus inactivation or removal uses caprylic acid (octanoic acid) at acidic pH. The method comprises caprylic acid treatment as part of the chromatographic step so as to perform viral inactivation without a discontinuous process and without the requirement of attention by personnel, particularly when the pH adjustment of the eluate is performed automatically by eluting into buffer. The method of the invention further results in mycoplasmas being inactivated, and reduced impurities like Host Cell Protein (HCP).


Patent
Novo Nordisk AS | Date: 2017-01-25

The present invention relates to an injection device for delivering set doses of a liquid drug to a user. The injection device has a scale drum for displaying the set dose, which scale drum is helically guided in a housing. The scale drum is thus rotational in relation to the housing between a zero position and a set position for displaying the set dose. Further, a needle cannula secured to a hub is mounted in an axially movable manner. The axial movement of the hub is generated by a spring. A blocking mechanism interacting between the scale drum and hub controls the axial movement of the hub such that the needle cannula automatically retracts from the skin of a user in response to the scale drum reaching the zero position.


Patent
Novo Nordisk AS | Date: 2017-02-08

The present invention relates to a needle arrangement for an injection device. The needle arrangement is made up from needle cannula which is mounted such that a distal part having a distal tip extends in a distal direction. Further, a telescopically movable shield carrying a cleaning chamber surrounds at least the tip of the needle cannula between injections such that the tip of the needle cannula is maintained inside the cleaning chamber between subsequent injections. The cleaning chamber is at least distally provided with a pierceable septum through which the needle cannula penetrates during injections. For guiding the needle cannula during injections a telescopically movable tube is provided. During injections the distal end of the telescopically movable tube at least partly penetrates the distal septum.


Patent
Novo Nordisk AS | Date: 2017-04-12

An add-on logging device (100, 300) mounted to a drug delivery device is turned on when the cap is removed. After a given amount of time in inactivity the sensor means of the add-on device is turned off automatically to save energy. If the user takes a dose of drug this is not detected as the add-on device is only turned on when the cap is removed. According to the present invention a warning message is provided when the cap is re-mounted after the sensor means has been turned off automatically, the warning message indicating to a user that an expelled dose may not have been detected.


Patent
Novo Nordisk AS | Date: 2017-01-19

The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.


Patent
Novo Nordisk AS | Date: 2017-03-08

Drug delivery device adapted to receive a cartridge, comprising a drive tube with an inner thread, a motor assembly comprising a drive shaft and being adapted to be received inside the drive tube, a drive member attached to the drive shaft and with an outer thread in engagement with the drive tube inner thread. The drive tube is arranged axially displaceable but non-rotational relative to the motor assembly, whereby rotation of the drive member results in axial, non-rotational displacement of the drive tube. To provide flexibility the drive shaft is connected to the drive member via a first flexible joint, and the motor assembly proximal portion is connected to a support structure via a second flexible joint.


Patent
Novo Nordisk AS | Date: 2017-01-06

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.


Patent
Novo Nordisk AS | Date: 2017-02-15

The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first Lys residue at a position corresponding to position 36 of GLP-1(7-37) (SEQ ID NO:1), a second Lys residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO : 1), and a maximum of seven amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 1); which derivative comprises two protractors attached to said first and second Lys residue, respectively, each via a linker; wherein the protractor is selected from : Chem. 1: HOOC-C6H4-0-(CH2)y-CO-*, and Chem. 2: HOOC-(CH2)x-CO-*, wherein y is an integer in the range of 8-11, and x is 12; and the linker comprises at least one of: Chem. 3: *-NH-CH(COOH)-(CH2)2-CO-*, Chem. 4: *-NH-CH((CH2)2-COOH)-CO-*, and/or Chem. 5: *-NH-(CH2)2-[0-(CH2)2]k-0-[CH2]n-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical uses thereof, such as for the treatment of diabetes and obesity, as well as to the GLP-1 peptides forming part of these derivatives which have Lys residues at positions 36 and 37 and no other Lys residues, and the GLP-1(9-37) fragments thereof. The invention furthermore relates to an intermediate product comprising 3-carboxyphenoxy-nonanoic acid with a protection group at the carboxy group of the nonanoic acid, optionally via a linker. The derivatives have a very good potency and a long half-life which makes them potentially useful for, e.g., oral administration.


Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a longer half-life was developed without changing the protein structure. FVIII-polyethylene glycol (PEG) conjugates were prepared using an enzymatic process coupling PEG (ranging from 10 to 80 kDa) selectively to a unique O-linked glycan in the FVIII B-domain. Binding to von Willebrand factor (VWF) was maintained for all conjugates. Upon cleavage by thrombin, the B-domain and the associated PEG were released, generating activated FVIII (FVIIIa) with the same primary structure and specific activity as native FVIIIa. In both FVIII- and VWF-deficient mice, the half-life was found to increase with the size of PEG. In vivo potency and efficacy of FVIII conjugated with a 40-kDa PEG (N8-GP) and unmodified FVIII were not different. N8-GP had a longer duration of effect in FVIII-deficient mouse models, approximately a twofold prolonged half-life in mice, rabbits, and cynomolgus monkeys; however, the prolongation was less pronounced in rats. Binding capacity of N8-GP on human monocyte-derived dendritic cells was reduced compared with unmodified FVIII, resulting in several-fold reduced cellular uptake. In conclusion, N8-GP has the potential to offer efficacious prevention and treatment of bleeds in hemophilia A at reduced dosing frequency.

Loading Novo Nordisk AS collaborators
Loading Novo Nordisk AS collaborators